Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abacavir-lamivudine versus tenofovir-emtricitabine in adults with HIV infection
ACTRN12605000505606Phase 4Not yet recruiting
- Sponsor
- The Kirby Institute
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of abacavir, lamivudine, tenofovir and emtricitabine in human immunodeficiency virus infection (HIV), sponsored by The Kirby Institute. Primary endpoint: Virological failure. Planned start Dec 2005; status: not yet recruiting.
02
Drugs
abacavirlamivudinetenofoviremtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ACTRN12605000505606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000505606.